Autolus Therapeutics plc - American Depositary Shares (AUTL)

Autolus (AUTL) Q1 2026 Earnings Transcript

Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy. Chief Executive Officer Dr. Christian Itin said the company h

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said.

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia.

AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.